| Title |
CARs in the Lead Against Multiple Myeloma
|
|---|---|
| Published in |
Current Hematologic Malignancy Reports, February 2017
|
| DOI | 10.1007/s11899-017-0373-2 |
| Pubmed ID | |
| Authors |
Maria Ormhøj, Felipe Bedoya, Matthew J. Frigault, Marcela V. Maus |
| Abstract |
The recent clinical success of CD19-directed chimeric antigen receptor (CAR) T cell therapy in chronic and acute leukemia has led to increased interest in broadening this technology to other hematological malignancies and solid tumors. Now, advances are being made using CAR T cell technology to target myeloma antigens such as B cell maturation antigen (BCMA), CD138, and kappa-light chain as well as CD19 on putative myeloma stem cells. To date, only a limited number of multiple myeloma patients have received CAR T cell therapy but preliminary results have been encouraging. In this review, we summarize the recently reported results of clinical trials conducted utilizing CAR T cell therapy in multiple myeloma (MM). |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 45% |
| Canada | 1 | 9% |
| Spain | 1 | 9% |
| Unknown | 4 | 36% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 82% |
| Scientists | 2 | 18% |
Mendeley readers
The data shown below were compiled from readership statistics for 87 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| Unknown | 86 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 14% |
| Student > Bachelor | 12 | 14% |
| Student > Ph. D. Student | 11 | 13% |
| Other | 8 | 9% |
| Student > Master | 8 | 9% |
| Other | 8 | 9% |
| Unknown | 28 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 22% |
| Agricultural and Biological Sciences | 9 | 10% |
| Immunology and Microbiology | 9 | 10% |
| Biochemistry, Genetics and Molecular Biology | 8 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
| Other | 7 | 8% |
| Unknown | 30 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 December 2023.
All research outputs
#2,465,990
of 25,734,859 outputs
Outputs from Current Hematologic Malignancy Reports
#33
of 449 outputs
Outputs of similar age
#44,829
of 325,359 outputs
Outputs of similar age from Current Hematologic Malignancy Reports
#2
of 13 outputs
Altmetric has tracked 25,734,859 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 449 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 325,359 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.